🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Centre Jean Perrin clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine and the EU Clinical Trials Information System (CTIS) — current trials in our France and EU (CTIS) registers with Centre Jean Perrin as lead sponsor. Synced 27 Sep 2026
16Current trials
8Recruiting now
5Drugs in these trials
2Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Centre Jean Perrin is the lead sponsor of 16 current clinical trials in our France and EU (CTIS) registers. 8 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Blood sample, Blood samples and Blood samples collection. The most-studied condition is Locally Advanced Head and Neck Carcinoma.

ClinicalTrials.gov trials by status

  • Recruiting853%
  • Not yet open17%
  • Active, closed640%

Trials by phase

  • Not applicable1067%
  • Observational320%
  • Phase 1/217%
  • Phase 217%
01

Clinical trials sponsored by Centre Jean Perrin

15 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
cDNA and Residual Disease After Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinomas
NCT07178847 · ClinicalTrials.gov ↗ · Locally Advanced Head and Neck Carcinoma
Not applicable Recruiting 2025-10 France
Xenografts Development From Surgical Tumor Samples of Patients With Triple Negative or Luminal B Breast Cancer
NCT04133077 · ClinicalTrials.gov ↗ · Breast Cancer Female
Not applicable Recruiting 2021-11 France
Prediction of Residual Disease by Circulating DNA Detection After Potentiated Radiotherapy for Locally Advanced Head and Neck Cancer
NCT05710679 · ClinicalTrials.gov ↗ · Locally Advanced Head and Neck Carcinoma
Not applicable Recruiting 2024-01 France
Impact of Implementing the Modified A-DIVA Scale on Successful Access to a Venous Line on the First Attempt
NCT06062199 · ClinicalTrials.gov ↗ · Chronic Disease
Not applicable Recruiting 2024-02 France
Augmented Reality Feasibility for Non-invasive Preoperative Tracking in Breast Cancer Surgery
NCT06512558 · ClinicalTrials.gov ↗ · Subclinical Breast Cancer Lesion
Not applicable Recruiting 2024-11 France
Identification of New Candidate Genes for Hereditary Predisposition to Uveal Melanoma
NCT06550674 · ClinicalTrials.gov ↗ · Uveal Melanoma
Not applicable Recruiting 2024-10 France
Identification of Genetic, Phenotypic, Clinical, Biological and Histological Factors Differentiating Patients With Ovarian Cancer Who Are Refractory to Platinum-based Therapy From Patients Defined as Long-term Responders to Platinum-based Therapy
NCT07361471 · ClinicalTrials.gov ↗ · Ovarian Cancer
Not applicable Recruiting 2026-01 France
Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-617 (Lu-PSMA) Treatment for Castration-resistant Metastatic Prostate Cancer
NCT06600802 · ClinicalTrials.gov ↗ · Castration-resistant Metastatic Prostate Cancer, Treated by 177Lutetium-PSMA-617 (Lu-PSMA)
Not applicable Recruiting 2024-10 France
Functional Imaging of Digital Osteoarthritis and Rheumatoid Arthritis Using 99mTc-NTP 15-5 in Nuclear Medicine
NCT07624994 · ClinicalTrials.gov ↗ · Digital Osteoarthritis or Rheumatoid Arthritis
Phase 2 Not yet open 2026-08 France
AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma
NCT04881032 · ClinicalTrials.gov ↗ · Glioblastoma
Phase 1/2 Active, closed 2022-03 France
Microbiota and the Lung Cancer
NCT03068663 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer
Not applicable Active, closed 2017-05 France
Support and Post-therapeutic Rehabilitation for Women in Complete Remission of Breast Cancer in a Thermal Environment
NCT05433077 · ClinicalTrials.gov ↗ · Non-Metastatic Breast Carcinoma, Remission, Quality of Life
Observational Active, closed 2022-06 France
Correlation Between TILs and Blood Cell Counts in Triple Negative Breast Cancer Patients
NCT04068623 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer
Observational Active, closed 2019-12 France
Interest of Broadband Spectroscopy Analysis by Infrared Laser on Liquid Biopsies in Breast Cancer Screening
NCT04273542 · ClinicalTrials.gov ↗ · Breast Cancer Female, BRCA1 Mutation, BRCA2 Mutation
Not applicable Active, closed 2021-05 France
Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse in Triple Negative Breast Cancer Patients
NCT04438681 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer
Observational Active, closed 2020-11 France

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Centre Jean Perrin in the EU trials register (CTIS)

1 trial

Authorised or ongoing trials in the EU Clinical Trials Information System with Centre Jean Perrin as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.

StudyPhaseStatusCountries
functional imaging of digital osteoarthritis and rheumatoid arthritis using 99mTc-NTP15-5 in nuclear medicine : phase II clinical study
2025-523650-14-00 · Not possible to specify
Phase 2 Authorised France
03

Drugs in Centre Jean Perrin trials

5 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

04

Conditions in Centre Jean Perrin trials

17 conditions
Locally Advanced Head and Neck Carcinoma2Triple Negative Breast Cancer2Breast Cancer Female2Glioblastoma1Non Small Cell Lung Cancer1Non-Metastatic Breast Carcinoma1Remission1Quality of Life1BRCA1 Mutation1BRCA2 Mutation1Chronic Disease1Subclinical Breast Cancer Lesion1Uveal Melanoma1Digital Osteoarthritis or Rheumatoid Arthritis1Ovarian Cancer1Castration-resistant Metastatic Prostate Cancer1Treated by 177Lutetium-PSMA-617 (Lu-PSMA)1
05

By trial register

RegisterTrialsRecruiting
Clinical trials in France158
EU register (CTIS)1—

A trial with sites in more than one country appears in each of those registers.

06

Questions about Centre Jean Perrin trials

How many clinical trials does Centre Jean Perrin sponsor?

Centre Jean Perrin is the lead sponsor of 15 current trials on ClinicalTrials.gov in our France register, and 1 authorised or ongoing trial in the EU register (CTIS), as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.

Are Centre Jean Perrin trials recruiting?

Yes. 8 of its 15 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Centre Jean Perrin testing?

Its current trials name 5 drugs and biologicals as interventions. The most frequent are Blood sample (1), Blood samples (1), Blood samples collection (1), Blood sampling (1) and Temozolomide (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 27 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.